Lightbridge Corporation — FY2022 Form 10-K
Reporting period: Fiscal year ended December 31, 2022; filed March 30, 2023. This is an annual report, not a quarterly filing. Lightbridge is a pre-revenue nuclear-fuel technology company developing metallic fuel for existing and future reactors.
Financial performance and position
| Metric | FY2022 / year-end | FY2021 / prior year-end |
|---|---|---|
| Revenue | $0 | $0 |
| General and administrative expense | $7.49 million | $7.16 million |
| Research and development expense | $0.67 million | $1.37 million |
| Operating loss | $7.79 million | $7.88 million |
| Net loss | $7.50 million | $7.84 million |
| Net loss per common share | $0.69 | $1.71 |
| Cash and cash equivalents | $28.90 million | $24.75 million |
| Net cash used in operations | $6.76 million | $11.04 million |
| Total assets | $29.47 million | $24.96 million |
| Current liabilities | $0.35 million | $0.17 million |
- Working capital was approximately $28.7 million at year-end 2022. The company reported no debt or lines of credit.
- Financing cash inflow was $10.92 million in 2022, principally $11.03 million of net proceeds from issuing approximately 1.9 million shares through its at-the-market (ATM) program.
- Revenue-based margins are not meaningful because the company had no revenue. The filing does not report a clear operating margin measure.
Changes versus FY2021
- Net loss narrowed by about $0.34 million. The 2022 loss per share also improved, but comparison is affected by 2021 preferred-stock dividends and deemed dividends associated with induced conversions; those items did not recur in 2022.
- Operating cash use fell by about $4.27 million, mainly because 2021 included a $4.2 million arbitration settlement payment.
- R&D expense declined by about $0.70 million, while G&A expense increased by about $0.33 million. Management attributed the R&D decline primarily to lower outside R&D and related costs.
- Cash increased by $4.15 million, supported by ATM issuance. Common shares outstanding rose from 9.76 million to 11.90 million during 2022.
Outlook, developments and principal risks
- Management said available cash was expected to cover business activities and operating cash needs for the next 12 months. It projected total expenditures of $13.1–$15.7 million over the next 12–15 months, including approximately $6.5 million for R&D. These are estimates, not guaranteed spending or financing outcomes.
- Longer-term development is expected to require average outside R&D spending of about $10 million annually over 10–15 years and several hundred million dollars in total funding. Management expects initial commercial fuel reload orders 15–20 years from the filing, subject to funding and development progress.
- In 2022, Lightbridge entered seven-year umbrella R&D agreements with Idaho National Laboratory’s operator, with initial work intended to support irradiation testing of fuel-material coupons. The filing anticipates coupon insertion in the Advanced Test Reactor in 2025; timing and subsequent testing remain uncertain.
- Key risks include dependence on government funding and political support, limited irradiation-test capacity, the need for experimental data and regulatory approvals, HALEU supply and infrastructure constraints, fabrication scale-up, commercial partners’ adoption, and competition from accident-tolerant fuels and other energy sources.
- The company is early-stage, has recurring losses and negative operating cash flow, and expects to need substantial additional capital. Further equity financing could dilute shareholders; the company’s public float was below $75 million and subject to “baby shelf” offering limits.
- Management identified a material weakness in accounts-payable invoice controls and concluded disclosure controls and internal control over financial reporting were ineffective at year-end. A remediation plan was underway but had not yet been demonstrated effective. The auditor issued an unqualified opinion on the financial statements but did not audit internal-control effectiveness.
- The filing reported no current pending legal proceedings known to the company. No income-tax provision was recorded; deferred tax assets were fully offset by a valuation allowance. A preliminary Section 382 analysis reduced reported available NOL carryforwards, without a net impact on the prior-period financial statements.
Important facts for investors to verify
- Cash runway against the company’s stated spending plans, and the availability and practical limits of future ATM or other financing.
- Progress and cost commitments under the INL agreements, access to test-reactor loops, and whether coupon irradiation and later testing meet the projected schedule.
- Whether Lightbridge can secure government funding, HALEU supply, fuel-fabrication capacity, utility and vendor partners, and required regulatory approvals.
- Whether the accounts-payable control weakness has been remediated and tested as effective.
- Future share issuance and dilution, including remaining ATM capacity and the impact of applicable public-float restrictions.